RGNX at a glance
REGENXBIO Inc. (RGNX, SEC CIK 1590877) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as November 3, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), REGENXBIO Inc. (RGNX) reported revenue of $170.4 million (up 104.5% from FY2024) and a net loss of $193.9 million. Diluted EPS was -$3.76.
- As of September 30, 2026, 28 institutional investment managers tracked by SignalX reported holding REGENXBIO Inc. (RGNX) shares worth $252.0 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by Ciongoli Gregory Austin on August 27, 2026 of 53,407 shares at $9.36 per share.
- In the last 90 days, RGNX insiders reported 2 open-market purchases ($949K) and 0 open-market sales ($0) on Form 4, a net purchase of $949K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $170.4M
- +104.5% vs prior year
- Insiders · 90 days
- 2 buys · 0 sells
- Net +$949K
- 13F holders
- 28 funds
- $252.0M · +1 vs prior quarter
- Latest 8-K
- Nov 5, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Revenue $9.2M, down $20.6M YoY from $29.7M, driven by lower Zolgensma royalties
- Operating loss $35.5M, versus $52.4M YoY; operating margin -387.8% vs -176.3%
- Best performer: Itvisma royalties $2.8M; worst: Zolgensma royalties $2.4M, down $21.2M YoY
- Cash, equivalents and marketable securities $251.0M; operating cash outflow $99.8M versus $71.7M YoY
- $107.8M equity offering and $18.9M ATM proceeds; liquidity expected into late fourth quarter 2027, with substantial going-concern doubt
Risk Factors
- No material changes from 2025 Form 10-K risk factors
- Carried-forward risks remain the company’s material disclosed risks
AI summary of the RGNX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Press release covers REGENXBIO’s quarter ended September 30, 2026
- Results of operations and financial condition details are in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Cash, equivalents and marketable securities $251.0M, plus $39.0M October settlement proceeds, funding operations into late Q4 2027
- Q3 revenue $9.2M vs $29.7M, reflecting $21.2M lower ZOLGENSMA royalties after U.S. patent expiration
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Kenneth T. Mills resigning as director effective October 21, 2026 to lead another company
- Departure unrelated to disagreements, reducing apparent governance or strategic disruption risk
Item 1.01: Entry into a Material Definitive Agreement
- $39.0 million payment from Sarepta due within 10 days of settlement effectiveness
- Settlement resolves all patent litigation involving ELEVIDYS and REGENXBIO’s 617 and 274 patents
AI summaries of RGNX 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for RGNX
Don't miss the next RGNX filing
- Alerts as it files. A push when RGNX files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut RGNX, by share count.
- Ask anything. An AI agent that reads every RGNX filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Malzahn Craig | A | Nov 1, 2026 | 27,777 | - |
| Christmas Patrick J. | A | Nov 1, 2026 | 34,722 | - |
| PAKOLA STEVE | A | Nov 1, 2026 | 34,722 | - |
| Chan Mitchell | A | Nov 1, 2026 | 24,305 | - |
| Malzahn Craig | F | Sep 1, 2026 | 234 | $9.32 |
| Chan Mitchell | F | Sep 1, 2026 | 4,902 | $9.32 |
| Ciongoli Gregory Austin | Buy | Aug 27, 2026 | 53,407 | $9.36 |
| Ciongoli Gregory Austin | Buy | Aug 26, 2026 | 49,196 | $9.14 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $83.3M | $170.4M |
| Operating Income | - | -$233.3M | -$161.2M |
| Net Income | -$263.5M | -$227.1M | -$193.9M |
| Op. Margin | - | -280.0% | -94.6% |
| Net Margin | - | -272.5% | -113.8% |
| Balance Sheet | |||
| Total Assets | $574.0M | $466.0M | $453.0M |
| Equity | - | $259.7M | $102.7M |
| ROE | - | -87.5% | -188.7% |
| Per Share | |||
| EPS | $-6.02 | $-4.59 | $-3.76 |
| Cash Flow | |||
| Operating CF | - | -$173.1M | -$124.0M |
| CapEx | $10.0M | $2.4M | $2.4M |
Source: XBRL data in REGENXBIO Inc. (RGNX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate RGNX share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 28 | $252.0M |
| Q2 2026 | 27 | $303.0M |
| Q1 2026 | 27 | $200.8M |
| Q4 2025 | 25 | $339.5M |
| Q3 2025 | 25 | $272.2M |
| Q2 2025 | 26 | $198.1M |
| Q1 2025 | 22 | $124.9M |
| Q4 2024 | 20 | $78.8M |
- T. Rowe Price Group+1.87M (+2956%)
- JPMorgan Chase & Co+1.35M (+61%)
- Vanguard Portfolio Management LLC+1.29M (+95%)
- BlackRock+1.28M (+20%)
- Two Sigma Investments+1.23M (+184%)
- Dimensional Fund Advisors−472.4K (-65%)
- Morgan Stanley−139.0K (-7%)
- Renaissance Technologies LLC−138.7K (-54%)
- Wells Fargo & Co−26.3K (-34%)
- Citigroup−23.0K (-30%)
- StoneX Group Inc.+10.8K
- Prudential Financial+10.3K
- FMR LLC (Fidelity)−342.9K
Source: 13F-HR filings on SEC EDGAR (aggregated from 200 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
RGNX filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Nov 5, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 4 | Nov 3, 2026 | - | - | - |
| 4 | Nov 3, 2026 | - | - | - |
| 4 | Nov 3, 2026 | - | - | - |
| 4 | Nov 3, 2026 | - | - | - |
| 8-K | Oct 16, 2026 | - | Analysis | - |
| 8-K | Sep 23, 2026 | - | Analysis | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Aug 27, 2026 | - | - | - |
| 8-K | Aug 25, 2026 | - | Analysis | - |
| 8-K | Aug 24, 2026 | - | Analysis | - |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 8-K | Jul 20, 2026 | - | Analysis | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 8-K | Jun 29, 2026 | - | Analysis | - |
| 8-K | Jun 3, 2026 | - | Analysis | |
| 4 | Jun 2, 2026 | - | - | |
| 4 | Jun 2, 2026 | - | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
RGNX SEC filings: frequently asked questions
Are RGNX insiders buying or selling?
In the last 90 days, REGENXBIO Inc. (RGNX) officers, directors and 10% owners reported 2 open-market purchases worth $949,381 by 1 insider and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold RGNX stock?
As of September 30, 2026, the largest REGENXBIO Inc. (RGNX) holders among the 13F filers tracked by SignalX were BlackRock ($57.8 million), JPMorgan Chase & Co ($26.5 million), State Street Corp ($23.7 million), Vanguard Portfolio Management LLC ($19.9 million), Vanguard Capital Management LLC ($19.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was RGNX's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), REGENXBIO Inc. (RGNX) reported revenue of $170.4 million (up 104.5% from FY2024) and a net loss of $193.9 million. Diluted EPS was -$3.76. The figures come from the XBRL data in the 10-K.
What did RGNX report in its latest 8-K?
REGENXBIO Inc. (RGNX) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Press release covers REGENXBIO’s quarter ended September 30, 2026.
What are the latest RGNX SEC filings?
REGENXBIO Inc. (RGNX) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on November 3, 2026.
What is RGNX's SEC CIK number?
REGENXBIO Inc. (RGNX)'s SEC Central Index Key (CIK) is 1590877. EDGAR lists every RGNX filing under that number.
Ask anything about RGNX
The research agent reads RGNX's filings, financials, insider trades and 13F holders, then answers with sources.